Arrowhead Pharmaceuticals, Inc. ((ARWR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Arrowhead Pharmaceuticals, Inc. is conducting a Phase 3 study titled ‘YOSEMITE’ to evaluate the efficacy and safety of Zodasiran in adolescents and adults with Homozygous Familial Hypercholesterolemia (HoFH). This study aims to address a critical need for effective treatments for HoFH, a genetic disorder that significantly elevates cholesterol levels, increasing the risk of cardiovascular diseases.
The intervention being tested is Zodasiran, administered via subcutaneous injection. This drug is designed to lower cholesterol levels in patients with HoFH, potentially offering a new therapeutic option for managing this condition.
The study is interventional with a randomized, parallel assignment model. It employs quadruple masking, meaning that the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment allocations. The primary purpose of the study is treatment-focused.
The study began on June 17, 2025, with the primary completion and estimated completion dates yet to be announced. The last update was submitted on July 9, 2025, indicating ongoing recruitment efforts.
This clinical update could positively impact Arrowhead Pharmaceuticals’ stock performance as successful results may enhance investor confidence and market position. The study’s progress is crucial for Arrowhead, especially in the competitive landscape of cholesterol-lowering therapies.
The YOSEMITE study is currently ongoing, with further details available on the ClinicalTrials portal.